Compare Exelon Corporation Common Stock (EXC) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Exelon Corporation Common Stock vs Globus Medical Inc. Class A Common Stock — how do they compare? Exelon Corporation Common Stock trades at $42.84 (market cap $43.89B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Exelon Corporation Common Stock is far larger — about 4.3× Globus Medical Inc. Class A Common Stock's market cap, and Exelon Corporation Common Stock pays a 3.94% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| EXC | GMED | |
|---|---|---|
Market Cap | $43.89B | $10.25B |
Volume | 7,093,882 | 1,059,528 |
Sector | Utilities | Health |
52-Week High | $50.29 | $96.82 |
52-Week Low | $40.20 | $58.33 |
Enterprise Value | $94.75B | $9.76B |
Dividend Yield | 3.94% | — |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Exelon (EXC) trades at $42.34, up 0.52% today, with a mixed technical picture showing a bullish overall signal but bearish moving averages and oscillators. The company reported strong earnings beats in recent quarters except for a Q2 2026 miss, with Q3 2026 results expected on October 30, 2026. Financials show solid profitability with a 10.99% net income margin and a P/E of 15.56, while cash flow trends indicate improving operational performance.
The outlook is cautiously optimistic, supported by a $48.11 analyst consensus price target and institutional accumulation, but risks include regulatory approvals for dividends and high RSI levels suggesting overbought conditions. Earnings growth and grid investment plans are key catalysts, though investor sentiment remains divided amid rate environment uncertainties.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Exelon Corporation Common Stock
Exelon is the parent company of six regulated electric and natural gas utilities. Its utilities include Atlantic City Electric, BGE, ComEd, Delmarva Power, PECO, and Pepco.
Read more on EXC →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
